Armando E. Giuliano: Difference between revisions

 

Line 25: Line 25:

=== Z011 trial===

=== Z011 trial===

The concept of sentinel lymph node biopsy was rapidly adapted by surgeons around the country. However, Giuliano wondered if the sentinel node is positive, would it be safe to take just that node and leave the others behind, potentially avoiding the morbid axillary dissection, though knowing that there is a likelihood that remaining nodes may have the disease? The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial was conducted to answer this question.{{Cite journal |last=Giuliano |first=Armando E. |last2=Ballman |first2=Karla V. |last3=McCall |first3=Linda |last4=Beitsch |first4=Peter D. |last5=Brennan |first5=Meghan B. |last6=Kelemen |first6=Pond R. |last7=Ollila |first7=David W. |last8=Hansen |first8=Nora M. |last9=Whitworth |first9=Pat W. |last10=Blumencranz |first10=Peter W. |last11=Leitch |first11=A. Marilyn |last12=Saha |first12=Sukamal |last13=Hunt |first13=Kelly K. |last14=Morrow |first14=Monica |date=2017-09-12 |title=Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial |url=https://pubmed.ncbi.nlm.nih.gov/28898379 |journal=JAMA |volume=318 |issue=10 |pages=918–926 |doi=10.1001/jama.2017.11470 |issn=1538-3598 |pmc=5672806 |pmid=28898379}} Giuliano authored the results of the Z0011 trial which showed that for women with T1 or T2 primary invasive breast cancer, without palpable axillary lymphadenopathy, and one or two nodes positive for malignancy, the ten-year survival for patients treated with sentinel lymph node biopsy alone was non-inferior to overall survival of patients treated with formal axillary lymph node dissection. This study was featured on the front page of [[The New York Times]].{{Cite news |last=Grady |first=Denise |date=2011-02-08 |title=Lymph Node Study Shakes Pillar of Breast Cancer Care |language=en-US |work=The New York Times |url=https://www.nytimes.com/2011/02/09/health/research/09breast.html |access-date=2023-05-05 |issn=0362-4331}}

The concept of sentinel lymph node biopsy was rapidly adapted by surgeons around the country. However, Giuliano wondered if the sentinel node is positive would it be safe to take just that node and leave the others behind axillary dissection, there a that remaining nodes may have the disease The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial was conducted to answer this question.{{Cite journal |last=Giuliano |first=Armando E. |last2=Ballman |first2=Karla V. |last3=McCall |first3=Linda |last4=Beitsch |first4=Peter D. |last5=Brennan |first5=Meghan B. |last6=Kelemen |first6=Pond R. |last7=Ollila |first7=David W. |last8=Hansen |first8=Nora M. |last9=Whitworth |first9=Pat W. |last10=Blumencranz |first10=Peter W. |last11=Leitch |first11=A. Marilyn |last12=Saha |first12=Sukamal |last13=Hunt |first13=Kelly K. |last14=Morrow |first14=Monica |date=2017-09-12 |title=Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial |url=https://pubmed.ncbi.nlm.nih.gov/28898379 |journal=JAMA |volume=318 |issue=10 |pages=918–926 |doi=10.1001/jama.2017.11470 |issn=1538-3598 |pmc=5672806 |pmid=28898379}} Giuliano authored the results of the Z0011 trial which showed that for women with T1 or T2 primary invasive breast cancer, without palpable axillary lymphadenopathy, and one or two nodes positive for malignancy, the ten-year survival for patients treated with sentinel lymph node biopsy alone was non-inferior to overall survival of patients treated with formal axillary lymph node dissection. This study was featured on the front page of [[The New York Times]].{{Cite news |last=Grady |first=Denise |date=2011-02-08 |title=Lymph Node Study Shakes Pillar of Breast Cancer Care |language=en-US |work=The New York Times |url=https://www.nytimes.com/2011/02/09/health/research/09breast.html |access-date=2023-05-05 |issn=0362-4331}}

Giuliano has authored over 500 peer-reviewed articles with around 45,000 citations.{{Cite web |title=Giuliano – ResearchGate |url=https://www.researchgate.net/profile/Armando-Giuliano}} During his academic career, he has served as the President of Society of Surgical Oncology, member of Board of Directors of Alliance for Clinical Trials in Oncology, and the President of International Sentinel Node Society. He has delivered lectures on clinical oncology and tumor biology at national and international forums. He joined [[Cedars-Sinai Medical Center]] in 2011 where he continues to investigate new ways to manage breast cancer, and works with a multi-disciplinary team to provide care to patients with range of breast pathologies. He also serves as…